MEDP vs ILMN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MEDP · Medpace$610.54 ▼ 3.70%
ILMN · Illumina$192.82 ▼ 3.90%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MEDP -1.3%
- ILMN +53.1%
Head to head
| Metric | MEDP | ILMN |
|---|---|---|
| Price | $610.54 | $192.82 |
| Change today | ▼ 3.70% | ▼ 3.90% |
| Market cap | $17.08B | $29.15B |
| Return, 3 months | -1.5% | -13.6% |
| Return, year to date | +8.7% | +47.0% |
| Return, 1 year | +3.2% | +55.7% |
| P/E (TTM) | 33.9 | 33.2 |
| P/B | 29.2 | 9.3 |
| P/E percentile vs own 5y | 60th | 77th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +8.5% | +4.2% |
| Net profit growth (YoY) | +23.7% | +46.7% |
| Gross margin | 29.1% | 67.9% |
| Operating margin | 21.4% | 21.4% |
| Net margin | 18.2% | 19.7% |
| Return on equity | 117.9% | 32.4% |
| Analyst target vs. price | +13.2% | +37.8% |
| Analyst buy share | 38% | 53% |
| RSI (14) | 38 | 34 |
| 30-day volatility | 35.6% | 78.8% |
| Max drawdown, 1 year | -36.6% | -34.3% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ILMN is the largest of the group by market value.
- ILMN has returned the most over the past year.
- ILMN carries the lowest trailing P/E.
- MEDP is growing revenue fastest.
- ILMN keeps the most profit per dollar of sales.
- MEDP has been the calmest stock over the last 30 days.